Novel Agents and Promising Combinations in Urothelial and Renal Cell Carcinoma - UroToday
Dr. Begona Perez-Valderrama discussed novel agents and combinations in RCC and urothelial carcinoma at the 2024 ESMO meeting, highlighting belzutifan's potential in RCC therapy and ongoing trials assessing various combinations, including antibody-drug conjugates like disitamab vedotin and trastuzumab deruxtecan.
Reference News
Novel Agents and Promising Combinations in Urothelial and Renal Cell Carcinoma - UroToday
Dr. Begona Perez-Valderrama discussed novel agents and combinations in RCC and urothelial carcinoma at the 2024 ESMO meeting, highlighting belzutifan's potential in RCC therapy and ongoing trials assessing various combinations, including antibody-drug conjugates like disitamab vedotin and trastuzumab deruxtecan.